Literature DB >> 33846396

An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan.

Jeffrey S Chang1, Li-Tzong Chen1,2,3, Yan-Shen Shan4,5, Pei-Yi Chu1,6,7, Chia-Rong Tsai1, Hui-Jen Tsai8,9,10.   

Abstract

The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996-2008 data from the Taiwan Cancer Registry. Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015. The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015. The most common site of NETs was rectum (29.65%), followed by lung/bronchus (17.22%), and pancreas (10.71%). The 5- and 10-year overall survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The survival of all NETs diagnosed between 2010 and 2015 was better than those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of pancreatic NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was observed. Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown a recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other sites in the near future.

Entities:  

Year:  2021        PMID: 33846396     DOI: 10.1038/s41598-021-86839-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  7 in total

Review 1.  Role of Somatostatin Signalling in Neuroendocrine Tumours.

Authors:  Olesja Rogoza; Kaspars Megnis; Marija Kudrjavceva; Aija Gerina-Berzina; Vita Rovite
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 2.  Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Authors:  Jack Cope; Raj Srirajaskanthan
Journal:  Curr Oncol Rep       Date:  2022-01-27       Impact factor: 5.075

3.  Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study.

Authors:  Angela Dalia Ricci; Sara Pusceddu; Francesco Panzuto; Fabio Gelsomino; Sara Massironi; Claudio Giovanni De Angelis; Roberta Modica; Gianluca Ricco; Martina Torchio; Maria Rinzivillo; Natalie Prinzi; Felice Rizzi; Giuseppe Lamberti; Davide Campana
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

Review 4.  Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Daisuke Takayanagi; Hourin Cho; Erika Machida; Atsushi Kawamura; Atsuo Takashima; Satoshi Wada; Takuya Tsunoda; Takashi Kohno; Kouya Shiraishi
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 5.  Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.

Authors:  Eun-Joo Park; Hyo-Jung Park; Kyung-Won Kim; Chong-Hyun Suh; Changhoon Yoo; Young-Kwang Chae; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

Review 6.  Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.

Authors:  Camilla Gallo; Roberta Elisa Rossi; Federica Cavalcoli; Federico Barbaro; Ivo Boškoski; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-03-21       Impact factor: 5.742

7.  Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study.

Authors:  Benjamin E White; Brian Rous; Kandiah Chandrakumaran; Kwok Wong; Catherine Bouvier; Mieke Van Hemelrijck; Gincy George; Beth Russell; Rajaventhan Srirajaskanthan; John K Ramage
Journal:  Lancet Reg Health Eur       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.